We searched MEDLINE, Embase, PsychInfo, the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and the Cochrane Central Register of Controlled Trials from inception to May 2020 for all studies that reported life participation in patients on PD. The characteristics, dimensions of life participation and psychometric properties of these measures were extracted and analyzed.
Of the 301 studies included, 17 (6%) were randomized studies and 284 (94%) were nonrandomized studies. Forty-two different measures were used to assess life participation. Of these, 23 (55%) were used in only one study. Fifteen (36%) measures were specifically designed to assess life participation, while 27 (64%) measures assessed broader constructs, such as quality of life, but included questions on life participation. The 36-Item Short Form Health Survey and Kidney Disease Quality of Life Short Form were the most frequently used measures [122 (41%) and 86 (29%) studies, respectively]. Eight (19%) measures had validation data to support their use in patients on PD.
The many measures currently used to assess life participation in patients receiving PD vary in their characteristics, content and validation. Further work to pilot and validate potential measures is required to establish a core patient-reported outcome measure to assess life participation in patients receiving PD.
我们搜索了MEDLINE,Embase,PsychInfo,护理和相关健康文献累积指数(CINAHL)和Cochrane中央对照试验注册从开始到2020年5月的所有报告PD患者生活参与的研究。的特点,提取并分析了这些测度的生活参与维度和心理测量特性。
在纳入的301项研究中,17项(6%)为随机研究,284项(94%)为非随机研究。使用42种不同的方法来评估生活参与。其中,23(55%)仅在一项研究中使用。15项(36%)措施是专门用于评估生活参与,虽然27项(64%)措施评估了更广泛的结构,比如生活质量,但包括关于生活参与的问题。36项简表健康调查和肾脏疾病生活质量简表是最常用的测量[122(41%)和86(29%)研究,分别]。八个(19%)的措施有验证数据,以支持他们在PD患者的使用。
目前用于评估接受PD的患者的生活参与的许多措施在其特征上有所不同,内容和验证。需要进一步的工作来试点和验证潜在的措施,以建立核心的患者报告的结果指标,以评估接受PD患者的生活参与。